Literature DB >> 25016619

Schedule of controlled substances: placement of tramadol into schedule IV. Final rule.

.   

Abstract

With the issuance of this final rule, the Deputy Administrator of the Drug Enforcement Administration places the substance 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol (tramadol), including its salts, isomers, and salts of isomers, into schedule IV of the Controlled Substances Act. This scheduling action is pursuant to the Controlled Substances Act which requires that such actions be made on the record after opportunity for a hearing through formal rulemaking. This action imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule IV controlled substances on persons who handle (manufacture, distribute, dispense, import, export, engage in research, conduct instructional activities with, or possess) or propose to handle tramadol.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25016619

Source DB:  PubMed          Journal:  Fed Regist        ISSN: 0097-6326


  11 in total

Review 1.  New directions in the treatment of opioid withdrawal.

Authors:  A Benjamin Srivastava; John J Mariani; Frances R Levin
Journal:  Lancet       Date:  2020-06-20       Impact factor: 79.321

2.  All-Cause Mortality Associated with Tramadol Use: A Case-Crossover Study.

Authors:  Sohyun Jeong; Ha Jin Tchoe; Junqing Li; Ju-Young Shin
Journal:  Drug Saf       Date:  2019-06       Impact factor: 5.606

3.  Individual short-acting opioids and the risk of opioid-related adverse events in adolescents.

Authors:  Cecilia P Chung; Stephen Todd Callahan; William O Cooper; William D Dupont; Katherine T Murray; Andrew D Franklin; Kathi Hall; Judith A Dudley; Charles Michael Stein; Wayne A Ray
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-08-16       Impact factor: 2.890

4.  Desmetramadol Has the Safety and Analgesic Profile of Tramadol Without Its Metabolic Liabilities: Consecutive Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trials.

Authors:  John A Zebala; Shawn L Searle; Lynn R Webster; Matt S Johnson; Aaron D Schuler; Dean Y Maeda; Stuart J Kahn
Journal:  J Pain       Date:  2019-04-18       Impact factor: 5.820

Review 5.  Drug Interaction and Serotonin Toxicity with Opioid Use: Another Reason to Avoid Opioids in Headache and Migraine Treatment.

Authors:  Hossein Ansari; Leila Kouti
Journal:  Curr Pain Headache Rep       Date:  2016-08

6.  Efficacy of Tramadol as a Sole Analgesic for Postoperative Pain in Male and Female Mice.

Authors:  A Marissa Wolfe; Lucy H Kennedy; Jane J Na; Jean A Nemzek-Hamlin
Journal:  J Am Assoc Lab Anim Sci       Date:  2015-07       Impact factor: 1.232

7.  Opioid Prescribing After Surgery in the United States, Canada, and Sweden.

Authors:  Karim S Ladha; Mark D Neuman; Gabriella Broms; Jennifer Bethell; Brian T Bateman; Duminda N Wijeysundera; Max Bell; Linn Hallqvist; Tobias Svensson; Craig W Newcomb; Colleen M Brensinger; Lakisha J Gaskins; Hannah Wunsch
Journal:  JAMA Netw Open       Date:  2019-09-04

8.  Clinical characteristics distinguishing tramadol-using adolescents from other substance-using adolescents in an out-patient treatment setting.

Authors:  A Holmstedt; M O Olsson; A Håkansson
Journal:  Addict Behav Rep       Date:  2020-03-31

9.  Single- and multiple-dose pharmacokinetics of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) compared with immediate-release hydrocodone bitartrate/ibuprofen and immediate-release tramadol HCl/acetaminophen.

Authors:  Krishna Devarakonda; Kenneth Kostenbader; Michael J Giuliani; Jim L Young
Journal:  J Pain Res       Date:  2015-09-30       Impact factor: 3.133

10.  Measuring Opioid Withdrawal in a Phase 3 Study of a New Analgesic, NKTR-181 (Oxycodegol), in Patients with Moderate to Severe Chronic Low Back Pain.

Authors:  Jack E Henningfield; Jeffrey Gudin; Richard Rauck; Joseph Gimbel; Mary Tagliaferri; Stephen K Doberstein; Carlo Di Fonzo; Lin Lu; Nathaniel Katz; Suresh Siddhanti; Sidney Schnoll
Journal:  Pain Med       Date:  2020-08-01       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.